Repligen Corporation (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Repligen Corporation (NASDAQ:RGEN) have earned an average recommendation of “Moderate Buy” from the twelve research firms that are currently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $166.6667.

Several research analysts have recently commented on RGEN shares. Barclays started coverage on Repligen in a research report on Tuesday, June 24th. They issued an “overweight” rating and a $150.00 target price for the company. Stephens upgraded Repligen to an “overweight” rating and set a $160.00 target price for the company in a research report on Tuesday, July 22nd. Evercore ISI decreased their target price on Repligen from $140.00 to $130.00 and set an “in-line” rating for the company in a research report on Tuesday, July 8th. Jefferies Financial Group decreased their target price on Repligen from $145.00 to $135.00 and set a “hold” rating for the company in a research report on Friday, September 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $180.00 target price on shares of Repligen in a research report on Wednesday, September 3rd.

Insider Activity at Repligen

In related news, Director Martin D. Madaus acquired 1,800 shares of Repligen stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the transaction, the director directly owned 1,800 shares of the company’s stock, valued at $201,834. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Hedge funds and other institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its position in shares of Repligen by 6.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company’s stock worth $962,711,000 after purchasing an additional 430,039 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of Repligen by 3,219.3% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock worth $51,422,000 after purchasing an additional 400,970 shares during the period. Geneva Capital Management LLC raised its position in shares of Repligen by 239.6% during the second quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock worth $60,639,000 after purchasing an additional 343,991 shares during the period. Blue Whale Capital LLP acquired a new stake in shares of Repligen during the second quarter worth $35,782,000. Finally, Nuveen LLC purchased a new position in shares of Repligen during the first quarter valued at $35,536,000. Institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

RGEN stock opened at $124.38 on Friday. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. Repligen has a 52-week low of $102.96 and a 52-week high of $182.52. The stock’s 50 day moving average is $119.94 and its two-hundred day moving average is $126.94. The company has a market capitalization of $7.00 billion, a PE ratio of -497.50, a P/E/G ratio of 2.20 and a beta of 1.07.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business had revenue of $182.37 million for the quarter, compared to analysts’ expectations of $174.62 million. During the same quarter in the prior year, the firm earned $0.40 earnings per share. Repligen’s revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Analysts predict that Repligen will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.